GLP1R and Hypoglycemia: In contrast, the GLP-1 receptor (GLP-1R) is thought to be one of the most important potential drug targets for glucose-dependent T2DM treatment, lowering hypoglycemia risk compared to insulin and sulfonylureas [11].